CMND CMND

Clearmind Medicine Stock Price

3.52
0.00 (0.0%)
3.52
Volume 0
Bid Price 3.42
Ask Price 4.49
News -
Day High

Low
3.00

52 Week Range

High
6.10

Day Low
Company Name Stock Ticker Symbol Market Type
Clearmind Medicine Inc CMND NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 3.52 04:08:25
Open Price Low Price High Price Close Price Prev Close
3.52
Trades Volume Avg Volume 52 Week Range
0 0 - 3.00 - 6.10
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 3.52 USD

Period:

Draw Mode:

Clearmind Medicine Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 8.71M 2.47M 2.47M $ - $ - -3.39 -0.60
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - -

more financials information »

Clearmind Medicine News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CMND Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week3.234.903.003.7477,7640.298.98%
1 Month5.426.103.004.8294,902-1.90-35.06%
3 Months5.426.103.004.8294,902-1.90-35.06%
6 Months5.426.103.004.8294,902-1.90-35.06%
1 Year5.426.103.004.8294,902-1.90-35.06%
3 Years5.426.103.004.8294,902-1.90-35.06%
5 Years5.426.103.004.8294,902-1.90-35.06%

Clearmind Medicine Description

Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.